Thomas Karn

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial

Sibylle Loibl, Gong Tang, Valentina Nekljudova, Priya Rastogi et autres

de, us, es, gb, ch, ca, pt (code pays fourni par la source)

Prognostic significance of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy

Altay Aliyev, Adila Adilli, Aydan Ismayilsoy, Farida Agayarlı et autres

az, us, de (code pays fourni par la source)

Interdisciplinary Implementation of the International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome: Care Gaps and Knowledge Deficits in Key High-Burden Domains

Annette Bachmann, Sandra Jordan, Thomas Karn, Daniela Chemogo-Gbellu et autres

de (code pays fourni par la source)

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort

Carsten Denkert, Sivaramakrishna Rachakonda, Anika Pehl, Frederik Marmé et autres

de, es, fr, kr, us, au, ca, ie, jp, at, gb (code pays fourni par la source)

Diagnostic accuracy of phosphatase and tensin homolog loss in differentiating between atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia and non‐atypical endometrial hyperplasia: A systematic review and meta‐analysis

Kristina Shcherbatiuk, Steffi Bultmann, Thomas Karn, Khayal Gasimli et autres

de (code pays fourni par la source)

Abstract PS4-08-07: Predicting response and survival after neoadjuvant systemic treatment with on-treatment biopsies

C. Denkert, A. Schneeweiss, V. Schaser, M. Untch et autres

de, pl, ch (code pays fourni par la source)

Abstract RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial

C. Denkert, Sivaramakrishna Rachakonda, Thomas Karn, A. Schneeweiss et autres

de, us, es, pt, ch (code pays fourni par la source)

Abstract RF2-01: Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) - a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials

Johannes Holtschmidt, A. Schneeweiss, Nadine Frickel, Natalie Filmann et autres

de, ee, pl (code pays fourni par la source)

Abstract PS3-08-19: Evaluation of stable calcium isotope ratios in women undergoing neoadjuvant chemotherapy (NACT) with and without denosumab (GeparX)

M. T. van Mackelenbergh, Theresa Link, C. Doering, Thomas Karn et autres

de, ch (code pays fourni par la source)

Prognostic impact of estrogen and progesterone receptor expression across histological subtypes and clinical factors in epithelial ovarian cancer

Athanasios Argyriadis, Khayal Gasimli, Alice Melodie Wilke, Iryna Schmeil et autres

de, az (code pays fourni par la source)

Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

Fabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, Isabella Sala et autres

it, de, us, ch (code pays fourni par la source)

Supplementary Figure S3 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

Terence M. Williams, Andreas Schneeweiß, Christian Jackisch, Changxian Shen et autres